Pembrolizumab as first-line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is?

Daniel A. Goldstein, Usama Bilal, Vinay Prasad

Research output: Contribution to journalComment/debatepeer-review

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)3872-3874
Number of pages3
Issue number20
StatePublished - Oct 15 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this